Clinical trials: High Grade Malignant Neoplasm
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment (refractory).
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT03587311
- Testing
- Anetumab Ravtansine, Bevacizumab, Paclitaxel
- Where
- 23 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Microsatellite High Cancers, Peritoneal Mesothelioma
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
- Conditions
- Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade, Neuroendocrine Carcinomas
- Trial name
- NCT05337735
- Testing
- XmAb20717
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer
A Study of Sovilnesib in Subjects With Ovarian Cancer
This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced…
- Conditions
- High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
- Trial name
- NCT06084416
- Testing
- Sovilnesib
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Volastra Therapeutics, Inc.
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
High Grade Gliomas, Glioblastoma
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well.
- Conditions
- High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- PRC (NCT07439172)
- Testing
- Pre-radiation temozolomide.
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cooper Health System
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Recurrent High-Grade Gliomas, Brain Neoplasm
A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade…
- Conditions
- Recurrent High-Grade Gliomas, Brain Neoplasm, Glioma
- Trial name
- NCT07826949
- Testing
- SRN-101, Blood Specimen Collection, Surgical Resection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nicholas Butowski
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis
- Trial name
- NCT02659241
- Testing
- Adavosertib, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).
- Conditions
- High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
- Trial name
- NCT05465954
- Testing
- Biospecimen Collection, Efineptakin alfa, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Mayo Clinic
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer.
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma
- Trial name
- NCT06639074
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Mayo Clinic
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections.
- Trial name
- NCT05998135
- Testing
- Atovaquone, Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Brain Tumor, Pediatric, Medulloblastoma, Childhood
GD2-CAR T Cells for Pediatric Brain Tumours
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory…
- Conditions
- Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor, High Grade Glioma
- Trial name
- NCT05298995
- Testing
- GD2-CART01 (iC9-GD2-CAR T-cells)
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent).
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma
- Trial name
- NCT02345265
- Testing
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate
- Where
- 20 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
- Trial name
- DENALI (NCT05128825)
- Testing
- azenosertib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 310 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High Grade Serous Ovarian Cancer (HGSOC)
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan.
- Trial name
- FAST HOC (NCT05956093)
- Testing
- FAPI PET CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)